Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. It is focused on human enzyme therapeutics to treat people with rare metabolic diseases. Its lead product candidate is pegzilarginase, which is a recombinant human arginase 1 tha... Read more
1 hour ago
MarketWatch
1 hour ago
MarketWatch
1 hour ago
CNBC
1 hour ago
MarketWatch
More Stock Analysis & Reports
Access to easy in-depth stock analysis and reports from Refinitiv with analyst estimates on share price movements.